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Qiliqiangxin (QL), a traditional Chinese
medicine, was approved by China Food
and Drug Administration for the treat-
ment of heart failure in 2004 (Li et al.,
2013). Our recent multicenter, ran-
domized, double-blind, parallel-group,
placebo-controlled study of the effects of
QL capsules in patients with chronic heart
failure shows that on a background of
standard treatment, QL capsules further
decreases the levels of plasma N-terminal
pro-B-type natriuretic peptide (NT-
proBNP) during 12 weeks of treatment
(Li et al., 2013). However, the underlying
mechanism is still unclear.
Recent progress in studying QL on
improving exercise tolerance and patients’
quality of life highlighted that QL may
be through a variety of biological mech-
anisms to exert its beneficial effects.
One possible mechanism may be the
regulation of the balance between pro-
inflammatory and anti-inflammatory
cytokines in cardiomyocytes (Xiao et al.,
2009). In addition, it may down-regulate
the cardiac chymase signaling pathway
and chymase-mediated AngII produc-
tion (Zhao et al., 2012). Moreover, it
may affect cardiomyocyte death and pro-
liferation, leading to improved cardiac
remodeling and cardiac function (Zou
et al., 2012).
Traditionally, the adult mammalian
heart is regarded as a post-mitotic
organ without any regenerative capac-
ity (Rosenzweig, 2012). Accumulating
evidence shows that cardiomyocytes in
adult mammals actually retain a limited
ability to proliferation (Rosenzweig, 2012).
Recently, a study shows that exercise
induce physiological hypertrophy featured
by cardiomyocyte hypertrophy and prolif-
eration. The cardiomyocyte proliferation
is mediated by the reduction of C/EBPß
and a linked increased of CBP/p300-
interacting transactivator with ED-rich
carboxyterminal domain 4 (CITED4)
(Boström et al., 2010). Interestingly, QL
has been reported to decrease C/EBPß and
also increase CITED4 at 4 weeks after
transverse aorta constriction induced
cardiac hypertrophy, remodeling and
dysfunction in mice (Zou et al., 2012).
The changes of C/EBPß and CITED4
are paralleled with enhanced prolifera-
tion of cardiomyocytes (Zou et al., 2012).
Moreover, our recent study also proves
that Huangqi (one of the major compo-
nents of QL) improves cardiac function
after acute myocardial infarction in mice
by regulating mTORC1 signaling pathway,
which also medicates cell proliferation
(Wu et al., 2013).
In conclusion, we think QL may mimic
a phenotype of physiological hypertrophy
and induce heart regeneration, which is
beneficial for heart failure.
REFERENCES
Boström, P., Mann, N., Wu, J., Quintero, P. A., Plovie,
E. R., Panáková, D., et al. (2010). C/EBPβ con-
trols exercise-induced cardiac growth and protects
against pathological cardiac remodeling. Cell 143,
1072–1083. doi: 10.1016/j.cell.2010.11.036
Li, X., Zhang, J., Huang, J., Ma, A., Yang, J., Li, W.,
et al. (2013). A multicenter randomized double-
blind parallel-group placebo-controlled study of
the effects of qiliqiangxin capsules in patients with
chronic heart failure. J. Am. Coll. Cardiol. 62,
1065–1072. doi: 10.1016/j.jacc.2013.05.035
Rosenzweig, A. (2012). Medicine. Cardiac regenera-
tion. Science 338, 1549–1550. doi: 10.1126/science.
1228951
Wu, X., Cao, Y., Nie, J., Liu, H., Lu, S., Hu, X., et al.
(2013). Genetic and pharmacological inhibition of
Rheb1-mTORC1 signaling exerts cardioprotection
against adverse cardiac remodeling in mice. Am. J.
Pathol. 182, 2005–2014. doi: 10.1016/j.ajpath.2013.
02.012
Xiao, H., Song, Y., Li, Y., Liao, Y. H., and Chen, J.
(2009). Qiliqiangxin regulates the balance between
tumor necrosis factor-alpha and interleukin-10
and improves cardiac function in rats with
myocardial function. Cell. Immunol. 260, 51–55.
doi: 10.1016/j.cellimm.2009.09.001
Zhao, J., Yang, P., Li, F., Tao, L., Ding, H., Rui, Y.,
et al. (2012). Therapeutic effects of astragaloside
IV on myocardial injuries: multi-target identifica-
tion and network analysis. PLoS ONE 7:e44938.
doi: 10.1371/journal.pone.0044938
Zou, Y., Lin, L., Ye, Y., Wei, J., Zhou, N., Liang, Y.,
et al. (2012). Qiliqiangxin inhibits the develop-
ment of cardiac hypertrophy, remodeling, and
dysfunction during 4 weeks of pressure overload
in mice. J. Cardiovasc. Pharmacol. 59, 268–280.
doi: 10.1097/FJC.0b013e31823f888f
Received: 07 October 2013; accepted: 09 October 2013;
published online: 24 October 2013.
Citation: Tao L, Shen S and Li X (2013) Future prospects
of Qiliqiangxin on heart failure: epigenetic regulation
of regeneration. Front. Genet. 4:221. doi: 10.3389/fgene.
2013.00221
This article was submitted to Epigenomics and
Epigenetics, a section of the journal Frontiers in
Genetics.
Copyright © 2013 Tao, Shen and Li. This is an
open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is
permitted, provided the original author(s) or licen-
sor are credited and that the original publication
in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduc-
tion is permitted which does not comply with these
terms.
www.frontiersin.org October 2013 | Volume 4 | Article 221 | 1
